Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Blagden

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 3, 2013
Intravenous versus oral dexamethasone premedication in preventing Paclitaxel infusion hypersensitivity reactions in gynecological malignanciesSean M O'Cathail, Roekshana Shaboodien, Sarah Mahmoud, et al.
BMC Cancer|March 14, 2020
A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocolNicholas F Brown, Stasya M Ng, Claire Brooks, et al.
Cancer Chemotherapy and Pharmacology|March 13, 2009
A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI), in patients with advanced solid tumoursEdwina N Scott, Anne L Thomas, L Rhoda Molife, et al.
British Journal of Cancer|April 29, 2023
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancerRebecca Kristeleit, Ruth Plummer, Robert Jones, et al.
Journal of Medical Genetics|June 28, 2020
Heritable genetic variants in key cancer genes link cancer risk with anthropometric traitsMatteo Di Giovannantonio, Benjamin Hl Harris, Ping Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2022
A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced CancerRobert Jones, Ruth Plummer, Victor Moreno, et al.
Neuro-Oncology|May 23, 2018
A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098Nicholas F Brown, Matthew Williams, Hendrik-Tobias Arkenau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2014
First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancerSarah Blagden, Aurelius Omlin, Aurelius Olmin, et al.
Nucleic Acids Research|December 17, 2020
The mTOR regulated RNA-binding protein LARP1 requires PABPC1 for guided mRNA interactionEwan M Smith, Nour El Houda Benbahouche, Katherine Morris, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 3, 2015
Dose-Finding Quantitative 18F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic MalignanciesHatice Gungor, Azeem Saleem, Syed Babar, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 3, 2013
Intravenous versus oral dexamethasone premedication in preventing Paclitaxel infusion hypersensitivity reactions in gynecological malignanciesSean M O'Cathail, Roekshana Shaboodien, Sarah Mahmoud, et al.
BMC Cancer|March 14, 2020
A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocolNicholas F Brown, Stasya M Ng, Claire Brooks, et al.
Cancer Chemotherapy and Pharmacology|March 13, 2009
A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI), in patients with advanced solid tumoursEdwina N Scott, Anne L Thomas, L Rhoda Molife, et al.
British Journal of Cancer|April 29, 2023
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancerRebecca Kristeleit, Ruth Plummer, Robert Jones, et al.
Journal of Medical Genetics|June 28, 2020
Heritable genetic variants in key cancer genes link cancer risk with anthropometric traitsMatteo Di Giovannantonio, Benjamin Hl Harris, Ping Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2022
A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced CancerRobert Jones, Ruth Plummer, Victor Moreno, et al.
Neuro-Oncology|May 23, 2018
A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098Nicholas F Brown, Matthew Williams, Hendrik-Tobias Arkenau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2014
First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancerSarah Blagden, Aurelius Omlin, Aurelius Olmin, et al.
Nucleic Acids Research|December 17, 2020
The mTOR regulated RNA-binding protein LARP1 requires PABPC1 for guided mRNA interactionEwan M Smith, Nour El Houda Benbahouche, Katherine Morris, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 3, 2015
Dose-Finding Quantitative 18F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic MalignanciesHatice Gungor, Azeem Saleem, Syed Babar, et al.
Pageof 4